Top

Published in:

01-10-2014 | Research Article

Expression and clinical significance of CRABP1 and CRABP2 in non-small cell lung cancer

Authors: Irina Favorskaya, Yaroslav Kainov, Galina Chemeris, Andrei Komelkov, Irina Zborovskaya, Elena Tchevkina

Published in: Tumor Biology | Issue 10/2014

Abstract

The impairment of retinoic acid (RA)-dependent signaling is a frequent event during carcinogenesis. Cellular retinoic acid-binding proteins (CRABP1 and CRABP2) are important modulators of RA activity. Up to date, the role of these proteins in cancer progression remains poorly investigated. Here, we studied for the first time the simultaneous messenger RNA (mRNA) and protein expression of CRABPs in non-small cell lung cancer (NSCLC) samples. CRABP1 and CRABP2 mRNA levels were elevated in 42 and 56 % of NSCLC samples, respectively. Decrease of CRABP2 mRNA expression was significantly associated with the presence of lymph node metastases. Protein expression of CRABP1 and CRABP2 was detected in 50 and 56 % of tumor samples, respectively. We also found a positive correlation between CRABP1 and CRABP2 expression. Taken together, we demonstrated significant changes in CRABP expression in NSCLC samples. Importantly, the presented data provide the first evidence of potential involvement of CRABP2 in lung cancer metastasis.

Available only for authorised users

Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 2010;62(13):1285–98. doi:10.1016/j.addr.2010.07.003.PubMedCentralCrossRefPubMed

Theodosiou M, Laudet V, Schubert M. From carrot to clinic: an overview of the retinoic acid signaling pathway. Cell Mol Life Sci CMLS. 2010;67(9):1423–45. doi:10.1007/s00018-010-0268-z.CrossRefPubMed

Dong D, Ruuska SE, Levinthal DJ, Noy N. Distinct roles for cellular retinoic acid-binding proteins I and II in regulating signaling by retinoic acid. J Biol Chem. 1999;274(34):23695–8.CrossRefPubMed

Budhu AS, Noy N. Direct channeling of retinoic acid between cellular retinoic acid-binding protein II and retinoic acid receptor sensitizes mammary carcinoma cells to retinoic acid-induced growth arrest. Mol Cell Biol. 2002;22(8):2632–41.PubMedCentralCrossRefPubMed

Ross AC. Cellular metabolism and activation of retinoids: roles of cellular retinoid-binding proteins. FASEB J Off Publ Fed Am Soc Exp Biol. 1993;7(2):317–27.

Won JY, Nam EC, Yoo SJ, Kwon HJ, Um SJ, Han HS, et al. The effect of cellular retinoic acid binding protein-I expression on the CYP26-mediated catabolism of all-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma. Metab Clin Exp. 2004;53(8):1007–12.CrossRefPubMed

Napoli JL. Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim Biophys Acta. 1999;1440(2–3):139–62.CrossRefPubMed

Fiorella PD, Napoli JL. Expression of cellular retinoic acid binding protein (CRABP) in Escherichia coli. Characterization and evidence that holo-CRABP is a substrate in retinoic acid metabolism. J Biol Chem. 1991;266(25):16572–9.PubMed

Tang XH, Vivero M, Gudas LJ. Overexpression of CRABPI in suprabasal keratinocytes enhances the proliferation of epidermal basal keratinocytes in mouse skin topically treated with all-trans retinoic acid. Exp Cell Res. 2008;314(1):38–51. doi:10.1016/j.yexcr.2007.07.016.CrossRefPubMed

10.

Tanaka K, Imoto I, Inoue J, Kozaki K, Tsuda H, Shimada Y, et al. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma. Oncogene. 2007;26(44):6456–68. doi:10.1038/sj.onc.1210459.CrossRefPubMed

11.

Lee HS, Kim BH, Cho NY, Yoo EJ, Choi M, Shin SH, et al. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(3):812–20. doi:10.1158/1078-0432.CCR-08-0266.CrossRef

12.

Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia. 2009;11(12):1329–39.PubMedCentralCrossRefPubMed

13.

Geiger T, Madden SF, Gallagher WM, Cox J, Mann M. Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res. 2012;72(9):2428–39. doi:10.1158/0008-5472.CAN-11-3711.CrossRefPubMed

14.

Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett. 2003;339(1):62–6.CrossRefPubMed

15.

Osanai M, Sawada N, Lee GH. Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1. Oncogene. 2010;29(8):1135–44. doi:10.1038/onc.2009.414.CrossRefPubMed

16.

Zhang Z, Joh K, Yatsuki H, Zhao W, Soejima H, Higashimoto K, et al. Retinoic acid receptor beta2 is epigenetically silenced either by DNA methylation or repressive histone modifications at the promoter in cervical cancer cells. Cancer Lett. 2007;247(2):318–27. doi:10.1016/j.canlet.2006.05.013.CrossRefPubMed

17.

Campos B, Centner FS, Bermejo JL, Ali R, Dorsch K, Wan F, et al. Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. Am J Pathol. 2011;178(5):1953–64. doi:10.1016/j.ajpath.2011.01.051.PubMedCentralCrossRefPubMed

18.

Miyake T, Ueda Y, Matsuzaki S, Miyatake T, Yoshino K, Fujita M, et al. CRABP1-reduced expression is associated with poorer prognosis in serous and clear cell ovarian adenocarcinoma. J Cancer Res Clin Oncol. 2011;137(4):715–22. doi:10.1007/s00432-010-0930-8.CrossRefPubMed

19.

Siddiqui NA, Thomas EJ, Dunlop W, Redfern CP. Retinoic acid receptors and retinoid binding proteins in endometrial adenocarcinoma: differential expression of cellular retinoid binding proteins in endometrioid tumours. Int J Cancer (J Int Cancer). 1995;64(4):253–63.CrossRef

20.

Jin BY, Fu GH, Jiang X, Pan H, Zhou DK, Wei XY, et al. CRABP2 and FABP5 identified by 2D DIGE profiling are upregulated in human bladder cancer. Chin Med J. 2013;126(19):3787–9.PubMed

21.

Banz C, Ungethuem U, Kuban RJ, Diedrich K, Lengyel E, Hornung D. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril. 2010;94(4):1212–7. doi:10.1016/j.fertnstert.2009.06.039.PubMedCentralCrossRefPubMed

22.

Kainov Y, Favorskaya I, Delektorskaya V, Chemeris G, Komelkov A, Zhuravskaya A et al. CRABP1 provides high malignancy of transformed mesenchymal cells and contributes to the pathogenesis of mesenchymal and neuroendocrine tumors. Cell Cycle. 2014;13(10).

23.

Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, et al. ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol Off J Int Soc Cell Oncol. 2006;28(5–6):259–72.

24.

Huang Y, de la Chapelle A, Pellegata NS. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer (J Int Cancer). 2003;104(6):735–44. doi:10.1002/ijc.11006.CrossRef

25.

Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell. 2007;129(4):723–33. doi:10.1016/j.cell.2007.02.050.PubMedCentralCrossRefPubMed

26.

Vreeland AC, Yu S, Levi L, de Barros Rossetto D, Noy N. Transcript stabilization by the RNA-binding protein HuR is regulated by cellular retinoic acid-binding protein 2. Mol Cell Biol. 2014;34(12):2135–46. doi:10.1128/MCB.00281-14.PubMedCentralCrossRefPubMed

27.

Jing Y, Waxman S, Mira-y-Lopez R. The cellular retinoic acid binding protein II is a positive regulator of retinoic acid signaling in breast cancer cells. Cancer Res. 1997;57(9):1668–72.PubMed

28.

Pfoertner S, Goelden U, Hansen W, Toepfer T, Geffers R, Ukena SN, et al. Cellular retinoic acid binding protein I: expression and functional influence in renal cell carcinoma. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2005;26(6):313–23. doi:10.1159/000089262.CrossRef

29.

Blaese MA, Santo-Hoeltje L, Rodemann HP. CRABP I expression and the mediation of the sensitivity of human tumour cells to retinoic acid and irradiation. Int J Radiat Biol. 2003;79(12):981–91. doi:10.1080/09553000310001632949.CrossRefPubMed

30.

Gupta S, Pramanik D, Mukherjee R, Campbell NR, Elumalai S, de Wilde RF, et al. Molecular determinants of retinoic acid sensitivity in pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(1):280–9. doi:10.1158/1078-0432.CCR-11-2165.CrossRef

Title: Expression and clinical significance of CRABP1 and CRABP2 in non-small cell lung cancer
Authors: Irina Favorskaya
Yaroslav Kainov
Galina Chemeris
Andrei Komelkov
Irina Zborovskaya
Elena Tchevkina
Publication date: 01-10-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 10/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2348-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2014

Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis

Association of vascular endothelial growth factor polymorphisms with clinical outcome of renal cell carcinoma patients

MMP-14 overexpression correlates with poor prognosis in non-small cell lung cancer

SOX10 is a novel oncogene in hepatocellular carcinoma through Wnt/β-catenin/TCF4 cascade

Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer

Identification of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer